Drugs in Pipeline
18
Phase 3 Programs
9
Upcoming Catalysts
1
Next Catalyst
Jun 15, 2026
| Drug Name | Phase |
|---|---|
Roflumilast Cream | Phase 3 |
Topical roflumilast | Phase 3 |
ARQ-151 Active | Phase 3 |
Roflumilast Cream 0.15% | Phase 3 |
ARQ-151 Cream 0.15% or ARQ-151 Cream 0.05% | Phase 3 |
Roflumilast 0.3% cream | Phase 3 |
Roflumilast Foam 0.3% | Phase 3 |
ARQ-151 0.3% cream | Phase 3 |
Roflumilast Foam | Phase 3 |
Roflumilast Cream 0.3% | Phase 2 |
ARQ-151 cream 0.3% | Phase 2 |
Vehicle foam | Phase 2 |
ARQ-252 cream 0.3% | Phase 2 |
ARQ-154 | Phase 2 |
Roflumilast | Phase 2 |
Roflumilast Cream 0.05% | Phase 2 |
ARQ-151 cream 0.5% | Phase 2 |
ARQ-151 cream 0.05% | Phase 2 |
1 upcoming, 0 past
Primary completion for ARQ-151 cream 0.05% trial (NCT06998056) in Atopic Dermatitis (Eczema)
Source